Biotech Values

[Caoi]

" Even after ACAD stock’s recent crash, ACADIA stock is still up almost 2,000% the last five years. "

" For the record, we think Nuplazid is going to be a smash hit, and that ACAD stock will continue its five year trajectory with massive long-term gains. Furthermore, we think expectations for Nuplazid’s first full year are too low, and that ACADIA Pharmaceuticals will beat those expectations easily.

Still, ACAD stock owners should look at PCYC as an indicator of what to expect. You will realize the next six months could be frustrating, but like PCYC, those who buy ACADIA stock on the dip will be rewarded long-term. "

https://bnlfinance.com/2016/10/14/acadia-pharmaceuticals-inc-acad-stock-owners-must-see-chart/